Objective: The present investigation was carried out to see whether intake of ®sh could in¯uence infarct size as assessed by peak enzyme levels (CK max and LD max ) as well as the occurrence of Q wave infarcts. Design: The investigation was a prospectively planned cohort study. Setting: The investigation was carried out at Ulleva Êl University Hospital, Department of Cardiology and Department of Pharmacotherapeutics, University of Oslo, Oslo, and in four other Hospitals in Oslo and Lillehammer. Subjects: Seven hundred and forty-®ve patients (median age 70 y, 64% males) admitted with proven acute myocardial infarction. 
Introduction
Observational, cohort and case-control studies indicate that eating ®sh may reduce mortality from coronary heart disease (CHD). In the Zutphen study, men who ate at least 30 g of any kind of ®sh every day had half the mortality from CHD compared to those who were consuming no ®sh at all (Kromhout et al, 1985) . The same favourable results on mortality and acute myocardial infarction (AMI) have been found in the Chicago Western Electric Study (Shekelle et al, 1985; Daviglus et al, 1997) , in a Swedish trial (Norell et al, 1986) , in the Usual Care arm of the Multiple Risk Factor Intervention Trial (Dolecek & Grandits, 1991) , among Italian women who had suffered an AMI (Gramenzi et al, 1990) and in elderly men and women in the Netherlands . In a randomised, controlled trial involving 2033 men who had recovered from AMI, a 29% reduction (risk ratio 0.71; 95% con®dence interval (CI) 0.54±0.93) in a 2 y all-cause mortality was found in those men who were advised to eat fatty ®sh (Burr et al, 1989) . The mean intake of eicosapentaenoic acid (EPA, n-3 fatty acid) at the end of 2 y was small, 2.5 gaweek corresponding to about 300 g of fatty ®sh. The risk for nonfatal plus fatal CHD events was 0.84; 95% CI 0.66±1.07. However, some other studies have been unable to ®nd any association between ®sh consumption and the risk of CHD (Vollset et al, 1985; Curb & Reed, 1985; Simonsen et al, 1987; Ascherio et al, 1995) . One such study did, however, suggest a protective effect of low-tomoderate ®sh intake on nonfatal MI, fatal CHD and any MI (Ascherio et al, 1995) . The reason for these discrepancies is unknown, but in some of these studies, the cohorts were characterized by high ®sh intake (Vollset et al, 1985; Curb & Reed, 1985) . In another study, the bene®cial effect of ®sh intake b 2aweek was only demonstrated in men who smoked more than 30 cigarettesad (Rodriguez et al, 1996) .
If regular ®sh consumption may be helpful in preventing CHD (including AMI), one would expect that ®sh intake would in¯uence development of infarct size and evolution. In patients admitted with AMI, we investigated if infarct size assessed by peak creatine kinase (CK max ) and lactate dehydrogenase (LD max ) as well as the occurrence of Q wave infarcts could be related to the number of ®sh servings being consumed every week. Q wave infarcts are usually transmural and their size larger than those described as non-Q wave infarcts (non-transmural).
Materials and methods
This is a cohort of 753 consequetive patients with proven AMI discharged alive from coronary care units. Four hospitals in Oslo and one in Lillehammer participated. Information of ®sh consumption was not available in eight patients, and the study population therefore consists of 745 patients. The patients were admitted in the period from August 1993 through June 1995. The diagnosis of AMI was based upon history (chest pain andaor dyspnea) increase in CK and LD and typical changes in the electrocardiogram. When CK increased within normal reference range, but there was doubt of whether this re¯ected myocardial necrosis, CK-MB measurements were in addition performed. Patients who were resuscitated or having their highest CK value on admission were not considered eligible in the study.
The demographic data of the patients, which were obtained from medical records and from personal interviews with each subject, are shown in Table 1 . The median age of the patients was 70 y, 64% being males. 400 patients (54%) had a history of previous coronary heart disease (CHD) (previous myocardial infarction andaor angina pectoris), and 256 (34%) reported a history of hypertension. Three hundred and thirty eight patients (45%) received thrombolytic treatment. Cardioactive drugs used at the onset of infarction are also shown in Table 1 .
A questionnaire was used in obtaining information regarding the number of ®sh mealsaweek (FMaweek) without specifying whether lean or fatty ®sh was consumed. No other information pertaining to usual food intake was collected. Median FMaweek was 1.6; 25% quartile and 75% quartile were 1.0 FMaweek and ! 2.6 FMaweek.
Peak enzyme levels in all patients and in the various subgroups are shown in Table 2 . CK max and LD max values were signi®cantly higher in patients receiving thrombolytic treatment. Peak enzyme levels were markedly elevated in patients with Q wave infarcts compared to those values found in non-Q wave infarcts (Table 2) . Previous CHD and prior use of aspirin, b-blockers, calcium blockers, angiotensin-converting enzyme inhibitors and long-acting nitrates were associated with smaller infarcts as assessed by peak enzyme levels (Table 2) .
Blood samples for CK and LD analyses were drawn on admission to hospital and approximately at 8, 16, 24 and 48 h thereafter. The CK reference ranges were 30±200 Ual for women and 40±250 Ual for men, the values for LD were 150±450 Ual for both women and men, while values below 540 Ual were considered normal in the elderlyÐolder than 60 y.
Crude effects
In the the ®rst analysis, we plotted the regression lines between FMaweek and CK max and LD max , respectively, for all the patients and the restricted cohorts of patients receivinganot receiving thrombolytic treatment. In the other analysis we estimated the occurrence of Q wave infarcts in patients consuming 1.0 FMaweek and b 1.0 FMaweek. The outcome was thus dichotomized, and in a 2 6 2 table the effect of FMaweek on Q wave infarcts was estimated by the odds ratio (OR) and its 95% con®dence interval (CI) (Hennekens et al, 1987) .
Adjusted effects
In an observational study it is necessary to adjust for the effects of confounders (age, gender, previous CHD, history of hypertension and prior use of aspirin, b-blockers, calcium blockers, angiotensin-converting enzyme inhibitors, diuretics and long-acting nitrates). This was done by using a multivariate regression model with log(CK max ) and log(LD max ) as continuous variables. In the dichotomized outcome relating to the occurrence of Q wave infarcts, we used the MantelHaenszel method (Rumeau-Rouquette et al, 1989) followed by the logistic regression model (Hosmer & Lemeskow, 1989) . Our strategy was explanatory and not pragmatic or predictive (Rumeau-Roquette et al, 1989) .
Results

Crude effects
The regression lines between the number of FMaweek and CK max in all the patients, also in the restricted cohorts of Eating ®sh may reduce infarct size K Landmark et al patients receivinganot receiving thrombolytic treatment are shown in Figure 1 . In all three groups, CK max was reduced with increasing number of ®sh servings, and the regression line between FMaweek and CK max in the total sample of patients was signi®cant (2P 0.004). The same pattern was seen between FMaweek and LD max (Figure 2 ), the regression line between FMaweek and LD max in the total sample of patients being signi®cant (2P 0.009). The difference in peak enzyme levels between patients receivinganot receiving thrombolytic treatment increased as infarct size increased (Figures 1 and 2 ). Eighty-one percent of the patients eating 1.0 FMa week developed Q wave infarcts, and of those consuming b 1.0 FMaweek and 1.6 FMaweek, b 1.6 FMaweek and 2.6 FMaweek and ! 2.6 FMaweek, 69, 68 and 68%, respectively, developed Q wave infarcts. OR for developing a Q wave infarct in patients eating b 1.0 FMaweek was 0.52; 95% CI 0.34±0.79, 2P 0.001 (Table 3 ). The median age of patients consuming 1.0 FMaweek and b 1.0 FMaweek was 68 and 71 y, respectively (2P`0.001). In addition, there were more male patients among those eating 1.0 FMaweek, 73% vs 61%, 2P 0.002.
Adjusted effects
The adjusted effects relating to FMaweek in all patients and in the restricted cohorts of patients receivinganot receiving thrombolytic treatment are shown in Table 4 . In all three groups, the coef®cients of FMaweek for log(CK max ) were negative, and in the ®rst two groups (all patients, and patients receiving thrombolytic treatment) statistically signi®cant with 2P values of 0.014 and 0.033, respectively (Table 4a ). The coef®cients of FMaweek for log(LD max ) were also negative for all three groups, being statistically signi®cant in the ®rst two groups (all patients, and patients receiving thrombolytic treatment) with 2P values of 0.006 and 0.033, respectively (Table 4b) .
The adjusted OR for developing a Q wave infarct in patients eating b 1.0 FMaweek was 0.59, 95% CI 0.38± 0.92, 2P 0.022.
Discussion
The present observational study indicates a negative association between ®sh consumption and infarct size as assessed by CK max and LD max . In addition, eating ®sh more than once a week may reduce the incidence of Q wave infarcts. The size of non-Q wave infarcts as assessed by LD max in patients not receiving thrombolytic treatment was similar to those found in a previous study (van der Laarse et al, 1988) . Assuming that one serving consists of approximately 250 g ®sh, median intake per week (1.6 FMaweek) in our study was 400 g or equivalent to 57 gad. This value is slightly higher than that found in a Figure 1 The regression lines between the number of ®sh meals per week (FMaweek) and CK max in all patients (n±n), in those receiving (s±s) and in those not receiving thrombolytic treatment (d±d).
Figure 2
The regression lines between the number of ®sh meals per week (FMaweek) and LD max in all patients (n±n), in those receiving (s±s) and in those not receiving thrombolytic treatment (d±d). Table, 1996) . Several previous studies have demonstrated bene®cial effects of ®sh intake on the development of CHD (Kromhout, et al, 1985; Shekelle et al, 1985; Norell et al, 1986; Burr et al, 1989; Gramenzi et al, 1990; Dolecek & Grandits, 1991; Kromhout et al, 1995; Daviglus et al, 1997) . In the Chicago Western Electric Study, independent, inverse graded associations between base-line ®sh consumption and the 30 y risk of death from CHD, particularly nonsudden death from myocardial infarction, were found (Daviglus et al, 1997) . Those men consuming 35 g or more of ®sh daily as compared to those who consumed no ®sh at all, the relative risk of death from CHD and from sudden or nonsudden myocardial infarction were 0.62 (95% CI 0.40±0.94) and 0.56 (95% CI 0.33±0.93), respectively. Others have also suggested that one or two servingsaweek may be of value (Kromhout et al, 1985; Shekelle & Stamler, 1993; Kromhout et al, 1995) ; while consuming more is not any better (Katan, 1995) . Yet another study supports this assumption. In a 12 y prospective cohort study involving 22.071 US male physicians, there were 115 sudden cardiac deaths (Albert et al, 1996) . Fish consumption had a bene®cial threshold effect which occurred ataor above 1.0 FMaweek. In the Multiple Risk Factor Interventional Trial, mean intake of n-3 fatty acids (EPA and docosahexaenoic acid (DHA)) was 0.18 gad (Dolecek & Grandits, 1991) . Among men determined to be at high risk of developing CHD, a 6±8 y mortality from CHD and cardiovascular disease was inversely associated with intake of n-3 fatty acids. In the largest intake quintile (0.66 gad), when compared with zero intake, mortality from CHD and cardiovascular disease was 40% and 41% lower. In the Zutphen study, two-third lean ®sh and onethird fatty ®sh were consumed in the group with the highest ®sh intake ( b 45 gad), the average amount of EPA was estimated to be 0.4 gad (Kromhout et al, 1985) . The patients in our study were not speci®cally asked whether their ®sh consumption consisted of lean or fatty ®sh, but we suggest that the ratio between the two types of ®sh was about the same as in the Dutch population. The daily consumption of ®sh in the coastal and inland areas of Northern Norway was 132 g and 55 g, respectively, representing intake of 0.9 g and 0.25 g EPA (Simonsen et al, 1987) . The content of n-3 fatty acids in platelet phospholipids and the bleeding time were similar in the two groups, while the collagen-induced platelet aggregation increased and triglyceride concentrations were higher in men from the coastal area. The effect of ®sh intake on s-triglycerides is, however, controversial. In another, larger study from the same area, ®sh intake was found to be inversely correlated to plasma triglycerides (Bùnaa et al, 1992) . In addition, a lowering effect on post-prandial triglyceride concentration has been demonstrated in a Swedish study (A Ê gren et al, 1996) . But, in this study, the ®sh group consumed 4.3 FMaweek and the daily intake of n-3 fatty acids was estimated to be as much as 1.05 gad. In a study from the Netherlands, there were no differences in s-triglycerides between elderly ®sh eaters (those consuming 24 g of ®shad) and non-®sh eaters .
As the content of n-fatty acids in lean ®sh is low, it has been questioned whether the inverse relation between consumption of lean ®sh and CHD could be explained by the effects of n-3 fatty acids on platelets and vessel wall interaction (Kromhout et al, 1985) . The concentration of EPA and DHA in serum phospholipids were higher in a high-®sh group (33 g ®shad) than in a low-®sh group (2 gad) (van Houwelingen et al, 1989) . No signi®cant differences, however, were observed between the two groups in cutaneous bleeding time, platelet number, collagen-induced platelet aggregation and ATP-release in whole blood. Thromboxane B2 content of whole blood and serum was similar in both groups. It has therefore been suggested that other nutrients, still unidenti®ed substances in ®sh other than n-3 fatty acids, may have protective effects (de Caterina, 1995) . However, even small amounts of n-3 fatty acids seem to be protective against CHD and sudden death. In a population-based case-control study, low intake of n-3 fatty acids (5.54 gamonth, equivalent to 3.7 servings of fresh salmonamonth), reduced the risk of primary cardiac arrest by 50% (Siscovick et al, 1995) . This bene®cial effect was associated with increased levels of mean red blood cell membrane n-3 fatty acids. In addition, intake of small amounts of n-3 fatty acids ( b 0.3. gamonth) was associated with a marked reduction in the relative risk of sudden death (Albert et al, 1996) . In patients with CHD, the concentrations of EPA in platelets and DHA in adipose tissue were inversely related to the disease (Aursnes et al, 1986; Wood et al, 1987; Seidelin et al, 1992; Hodgson et al, 1993) . Incorporation of n-3 polyunsaturated fatty acids in phospholipids may exert a positive effect on the physical properties of cell membranes , and arterial compliance in non-®sh eaters was signi®cantly lower than in ®sh eaters (Wahlquist et al, 1989) .
Due to increased wash-out, peak enzyme levels, especially CK max , were higher in patients receiving thrombolytic treatment at entry to the hospital. The increased differences in CK max and LD max between patients receivinganot receiving thrombolytic treatment with greater infarct size are in accordance with results found in another study (Blanke et al, 1984) . Patients treated with streptokinase experienced a relative greater release of CK for a given infarct size as compared with those treated in a conventional manner (Blanke et al, 1984) . LD is released more slowly and appears to be less sensitive to this washout effect (Karagounis et al, 1991) , as shown in the present study. Patients with angina pectoris andaor healed myocardial infarction developed smaller infarcts assessed by CK max and LD max , and this observation is consistent with previous ®ndings (Brush et al, 1988) . Angina was more prevalent in patients with good collateral circulation (Fischer Hansen, 1989) . The presence of coronary collateral vessels at the onset of AMI was correlated with limitation of infarct size as estimated enzymatically (Habib et al, 1991; Sabia et al, 1992) .
Conclusions
In our analysis we have tried to minimize potential bias by adjusting for confounders. Although the possibility for residual confounding by unmeasured factors cannot be quite excluded, we conclude that our results indicate that consuming ®sh more than once per week may reduce infarct size as well as the occurrence of Q wave infarcts. These ®ndings may explain, at least to some degree, the reduced mortality from CHD in ®sh eating subjects.
